Google
Trusted Resources: News & Events
Latest announcements and gatherings
Ghana Launches Partnership With Novartis to Improve Diagnosis and Treatment of People With Sickle Cell Disease
The Government of Ghana announced a new public-private partnership to improve the diagnosis and accelerate treatment for people with sickle cell disease (SCD), making Ghana the first African country to commit to offering the global standard of care for their people with SCD.
The Ministry of Health of Ghana, Ghana Health Service, the Sickle Cell Foundation of Ghana and global medicines company Novartis have signed a Memorandum of Understanding to create a holistic approach to help tackle the disease. The partnership aims to improve and extend the lives of people with SCD through a comprehensive approach to screening and diagnosis; treatment and disease management; training and education; and elevating basic and clinical research capabilities.
Specifically, the partners aim to collaborate on field testing and implementation of SCD treatment guidelines, the establishment of centers of excellence across regions and the implementation of newborn screening at these centers.
+myBinderRelated Content
-
Adverse Reactions to Pneumococcal Vaccine in Pediatric and Adolescent Patients with Sickle Cell DiseaseSTUDY OBJECTIVE: To review five cases o...
-
Sickle Cell Disease: Nutritional ConsiderationsPatients with sickle cell anemia have gr...
-
CRISPR deployed to combat sickle-cell anaemiaA mutation in a single DNA letter causes...
-
Facebook Live: Stem Cells and Sickle Cell Diseasehttps://www.youtube.com/watch?v=IPzNx8i_...
-
Emmaus, a leader in sickle cell disease treatment, signs agreement with Cardinal Health to solidify distribution net...Emmaus Life Sciences, Inc. announces...
-
Bluebird bio acquires Durham, NC, manufacturing site for lentiviral vector productionbluebird bio said today it has acquired ...
-
Potential treatment targeting nitric oxide levels, olinciguat, named orphan drug by FDAThe U.S. Food and Drug Administration ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.